A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study
Authors Roland Asmar, Sophie Nisse-Durgeat
Published 15 September 2006 Volume 2006:2(3) Pages 317—323
Roland Asmar1, Sophie Nisse-Durgeat2
1The Cardiovascular Institute, Paris, France; 2Laboratoire Takeda, Puteaux, France
Abstract: This 8-week, multicenter study evaluated the efficacy and safety of candesartan cilexetil (CC, 8–16 mg) in elderly (>65 years) hypertensive patients. Patients (n=3013) received CC 8 mg during 8 weeks which eventually doubled to CC 16 mg at week 4 if blood pressure remained uncontrolled (>140/90 mmHg). At week 8, 65.5% of patients were normalized (BP <140/90 mmHg). Mean changes at week 8 were –25.8, –13.2, and –12.7 mmHg for systolic, diastolic, and pulse pressure, respectively. Age, sex, and diabetic status did not influence the antihypertensive effect of CC. 68% of the patients treated with, but uncontrolled or intolerant of, prior antihypertensive treatment were normalized by CC 8–16 mg. In summary, CC 8– 16 mg once daily was effective and well tolerated in the management of arterial hypertension in elderly subjects.
Keywords: candesartan cilexetil, angiotensin II receptor antagonist, hypertension, elderly subject, CHANCE study